Job title: Senior Scientific Fellow and Head, Technology Excellence
Mark Henson has a PhD in bio-inorganic chemistry from Stanford University. He has held various R&D roles involving PAT and predictive modeling across the pharmaceutical, embryology, and chemicals spaces at Pfizer, Molecular Biometrics LLC, and the ExxonMobil Chemical Co (respectively). He has also gained insight into various Quality and Regulatory topics in the GMP space as a Director of Analytical Technology at Shire, notably during development of a PAT-based control strategy for a pilot continuous manufacturing effort. Most recently he joined Takeda R&D as a Senior Scientific Fellow in the Innovation and Technology Sciences team, and serves as Program Head for their ambitious and cross-functional/modality Pharmaceutical Sciences Technology Strategy. Mark has also volunteered extensively in various roles with USP, first as member of the Chemometrics Expert Panel with authored the <1039> guidance chapter, and more recently as a member of the General Chapters Chemical Analysis Expert Committee.
Continuous Processing in the Context of a Broader Pharmaceutical Development Technology Strategy 10:20 am
• Continuous processing value proposition for development vs. commercial organizations • Roadmap approach facilitates parallel implementation of critical supporting Pharma 4.0 elements • Modality-agnostic platform digital architectures and project frameworks facilitate rapid adoptionRead more
day: Day Two